ALKemist Bio
Developer of cellular immunotherapies designed to target ALK-positive cancer cells through engineered T-cell receptors. The company's platform utilizes a process that extracts, modifies and reinfuses ...
Valuation
$0
Share Price
N/A
Total Raised
$7.6M
Last Round
N/A